Adc Therapeutics

Adc Therapeutics company information, Employees & Contact Information

Explore related pages

Related company profiles:

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. We are a pioneer in the ADC field with specialized capabilities unique to ADCs from clinical to manufacturing and commercialization with a proven track record that includes an approved and marketed product. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.

Company Details

Employees
322
Founded
-
Address
Lausanne, Vaud, Switzerland, Ch
Phone
+1 908-731-5556
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Lausanne, Vaud, Switzerland
Looking for a particular Adc Therapeutics employee's phone or email?

Adc Therapeutics Questions

News

ADC Therapeutics to Present at November Investor Conferences - Morningstar

ADC Therapeutics to Present at November Investor Conferences Morningstar

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - PR Newswire

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference PR Newswire

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress - Yahoo Finance

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress Yahoo Finance

Leading ADC Biotech Company Sets Q2 Earnings Call: What to Expect from ADC Therapeutics - Stock Titan

Leading ADC Biotech Company Sets Q2 Earnings Call: What to Expect from ADC Therapeutics Stock Titan

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma - PR Newswire

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma PR Newswire

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - PR Newswire

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma PR Newswire

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update - PR Newswire

ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update PR Newswire

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - PR Newswire

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 PR Newswire

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 - PR Newswire

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 PR Newswire

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) - PR Newswire

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) PR Newswire

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants - GlobeNewswire

ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants GlobeNewswire

ADC Therapeutics to Present at Upcoming Investor Conferences - Stock Titan

ADC Therapeutics to Present at Upcoming Investor Conferences Stock Titan

ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer - Business Wire

ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer Business Wire

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma - Business Wire

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma Business Wire

ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) - FinancialContent

ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) FinancialContent

ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer - FinancialContent

ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer FinancialContent

Swiss Phase 2 biotech developing next-gen antibody drug conjugates for difficult cancers. - renaissancecapital.com

Swiss Phase 2 biotech developing next-gen antibody drug conjugates for difficult cancers. renaissancecapital.com

ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company - GlobeNewswire

ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company GlobeNewswire

ADCT - Adc Therapeutics Sa Latest Stock News & Market Updates - Stock Titan

ADCT - Adc Therapeutics Sa Latest Stock News & Market Updates Stock Titan

ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report - FinancialContent

ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report FinancialContent

Top Adc Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant